Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prolonged prophylaxis in postoperative medicine

D Bergqvist1

  • 1University Hospital, Department of Surgery, Uppsala, Sweden.

Seminars in Thrombosis and Hemostasis
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cranial nerve injuries after carotid artery surgery. A prospective study of 663 operations.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·1995
Same author

[Arterial surgery of the extremities without angiography. A simpler preoperative survey with color doppler].

Lakartidningen·1995
Same author

The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin.

Haemostasis·1995
Same author

Intraplaque haemorrhage at carotid artery surgery--a predictor of cardiovascular mortality.

Journal of internal medicine·1995
Same author

[Vascular surgeons make comparison with the USA. Low level of Swedish control over implants].

Lakartidningen·1995
Same author

Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS).

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·1995

Extended prophylaxis after hip surgery significantly reduces deep vein thrombosis (DVT). Continuing anticoagulant therapy post-discharge is crucial for preventing potentially fatal pulmonary embolism (PE).

Area of Science:

  • Orthopedic Surgery
  • Vascular Medicine
  • Pharmacology

Background:

  • Major orthopedic surgeries like hip or knee replacement carry a high risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).
  • Current thromboprophylaxis guidelines often involve short durations, leading to an increase in late-onset PE after hospital discharge.
  • The optimal duration of anticoagulant prophylaxis following major surgery remains uncertain.

Purpose of the Study:

  • To evaluate the efficacy of extended post-discharge prophylaxis in preventing DVT after hip arthroplasty.
  • To determine if continuing low-molecular-weight heparin (LMWH) therapy after hospital discharge reduces the incidence of DVT.

Main Methods:

  • Four studies involving hip arthroplasty patients were analyzed.
  • Prophylaxis was administered using low-molecular-weight heparins (enoxaparin or dalteparin).

Related Experiment Videos

  • In-hospital treatment ranged from 7 to 15 days, with post-discharge prophylaxis lasting 21 to 28 days. Deep vein thrombosis (DVT) was diagnosed via bilateral venography.

    • Main Results:

    • All trials demonstrated a significant reduction in DVT incidence in patients receiving extended post-discharge prophylaxis compared to controls.
    • The use of LMWH post-discharge led to a marked decrease in DVT rates in hip arthroplasty patients.
    • It is inferred that this reduction in DVT also positively impacts the frequency of potentially fatal pulmonary embolism (PE).

    Conclusions:

    • Extended thrombosis prophylaxis should be continued after hospital discharge for patients undergoing major surgical procedures, particularly hip arthroplasty.
    • Low-molecular-weight heparins (LMWH) are effective in reducing DVT when administered post-discharge.
    • Continuation of prophylaxis is recommended, especially in patients with persistent risk factors for venous thromboembolism.